The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...
Acupath Laboratories announced today the integration of the ArteraAI Prostate Test into its diagnostic workflows, allowing for fast and convenient delivery of treatment insights. The ArteraAI Prostate ...
Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers ...
OncoAssure Ltd, an Irish medical diagnostic company, announced the publication of new data in the journal BJUI Compass that demonstrate the clinical validation of OncoAssure Prostate, a novel biopsy ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...
Artera, a company that develops multimodal AI-based prognostic and predictive cancer tests, has been granted Breakthrough Device Designation by the FDA for its ArteraAI Prostate, an AI-enabled tool ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results